.svg)
Xovoltib 30 Mg
Price range: $185.00 through $540.00
Xovoltib 30 Mg is a targeted EGFR inhibitor used to treat non-small cell lung cancer by blocking cancer cell growth signals.
Description
Xovoltib 30 Mg
Xovoltib 30 Mg is a targeted anticancer medication used in the treatment of non-small cell lung cancer (NSCLC), particularly in patients with epidermal growth factor receptor (EGFR) mutations. It contains afatinib, a second-generation tyrosine kinase inhibitor (TKI) that blocks cancer cell growth signals. This intermediate-strength formulation is commonly prescribed when dose optimization is required based on patient response and tolerability. In treatment strategies, lower doses such as Xovoltib 20 Mg may be used for better tolerability, while higher strengths like Xovoltib 40 Mg are often considered for standard or more intensive therapy.
Mechanism of Action
EGFR Inhibition
Xovoltib 30 Mg works by irreversibly inhibiting EGFR and related receptors involved in cancer cell growth and survival.
Targeted Antitumor Activity
By blocking these pathways, it prevents tumor cell proliferation and promotes cancer cell death. For detailed clinical insights, refer to National Cancer Institute (NCI) and for safety information, consult Mayo Clinic – Afatinib Drug Information.
Medical Uses
Xovoltib 30 Mg is used in:
- EGFR mutation-positive non-small cell lung cancer (NSCLC)
- Advanced or metastatic lung cancer
It is often prescribed as part of first-line or adjusted therapy depending on patient needs.
Dosage and Administration
Xovoltib 30 Mg is typically taken once daily on an empty stomach, as directed by an oncologist. The dosage is individualized based on response and side effects. In clinical practice, Xovoltib 20 Mg may be used for dose reduction, while Xovoltib 40 Mg is commonly prescribed as a standard higher-dose option for eligible patients.
Clinical Effectiveness
Clinical studies have demonstrated that afatinib improves progression-free survival and provides effective disease control in patients with EGFR mutation-positive NSCLC. The 30 mg dose offers flexibility in balancing efficacy and tolerability.
Safety and Side Effects
Common Side Effects
- Diarrhea
- Skin rash
- Mouth sores
- Nail changes
Serious Risks
- Severe diarrhea and dehydration
- Interstitial lung disease
- Liver toxicity
Regular monitoring is essential during therapy. For more details, refer to Mayo Clinic – Afatinib Drug Information.
Contraindications and Precautions
Xovoltib 30 Mg should be used with caution in:
- Patients with lung disorders
- Individuals with liver impairment
- Patients with gastrointestinal conditions
It should not be used during pregnancy unless prescribed.
Drug Interactions
Xovoltib 30 Mg may interact with medications affecting liver enzymes and other anticancer drugs. Patients should inform their healthcare provider about all medications they are taking. For research-based insights, refer to National Cancer Institute (NCI).
FAQs
Xovoltib 30 Mg is used to treat EGFR mutation-positive non-small cell lung cancer. It helps control tumor growth and is often prescribed based on patient response and tolerance to therapy.
Xovoltib 30 Mg works by blocking EGFR proteins that drive cancer cell growth. This helps prevent cancer cells from multiplying and supports disease control.
Xovoltib 30 Mg is effective but may cause side effects such as diarrhea and skin rash. Serious risks include lung inflammation and liver toxicity. Regular monitoring is required during treatment.
Xovoltib 30 Mg can interact with other medications, especially those affecting liver enzymes. Patients should inform their doctor about all medicines they are taking to ensure safe treatment.
The duration of treatment depends on the patient’s condition and response. It is usually taken long-term under medical supervision to maintain disease control.
RELATED PRODUCTS
Cabozantinib Tablets 40 Mg – Cazanat
Enzalutamide 80 Mg – Generic Xtandi
Everolimus Tablets 0.5 Mg – Generic Afinitor
Fluorouracil Injection 500 Mg – Generic Adrucil
